Physician profile
Brian P Senger
NPI 1194722660
$11,514.97
in general payments reported to CMS, 2019-2025
58 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,581 · 2020: $1,314 · 2021: $1,547 · 2022: $1,868 · 2023: $2,179 · 2024: $1,807 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,165 · Education: $39.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,165.39 |
| Education | $39.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,633.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,130.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,090.55 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,036.14 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $821.68 | 2019-2024 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $646.99 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $581.87 | 2019-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $470.32 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $346.77 | 2019-2023 | Belsomra, Steglatro |
| Sanofi-Aventis U.S. LLC | $313.79 | 2019-2025 | |
| Pfizer INC. | $280.70 | 2022-2025 | |
| Esperion Therapeutics, INC. | $264.87 | 2020-2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $205.57 | 2020-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $200.77 | 2023-2024 | Rexulti |
| Astellas Pharma US INC | $200.44 | 2022-2025 | Veozah, Myrbetriq |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Senger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.